HealthRX review

$99 a month for compounded semaglutide is a 12-month prepay: $1,188 charged once, up front. Bought a month at a time the same medication is $190, or $149 for a first month that then renews at $165 on Subscribe & Save. Tirzepatide follows the same shape one tier higher — $179 a month only at twelve months, $2,148 in a single charge, against $239 with no commitment.

There are four rungs on each molecule, and the per-month figure falls as the term lengthens. Semaglutide is $190 a month with no term ($149 first month, then $165), $399 for three months ($133 a month), $714 for six months ($119 a month), and $1,188 for twelve ($99 a month). Tirzepatide is $239 a month with no term ($193 first month, then $214), $627 for three months ($209 a month), $1,194 for six months ($199 a month), and $2,148 for twelve ($179 a month).

Renewals come in below the signup price, which is unusual enough to plan around. Every renewal carries a standing $25 subscriber credit, so the 12-month semaglutide plan renews at $1,163 rather than $1,188, and the tirzepatide plan at $2,123 rather than $2,148. The prices are self-dated on the pricing page — "Prices current as of July 28, 2026" — which is a month old at this writing, and considerably better than the undated price tables most cash-pay sites publish.

Nothing is stacked on top of those figures. HealthRX states there are no separate visit fees and no membership fees, promises a full refund if a provider does not approve you, ships free and overnight, and accepts HSA and FSA payment. What you are buying is a compounded medication rather than an FDA-approved one, which is the trade every rung on this ladder is built on.

HealthRX publishes a LegitScript certification number, 50087439, and runs a licensed-provider intake with physician supervision behind it. That does not make a compounded drug an approved one, and it is not a substitute for asking which pharmacy fills your prescription. The number is the company's own claim rather than a finding of ours: the image LegitScript serves is the same for every valid id, so it shows the id exists rather than that this seller holds the certification.

The GLP-1 offer is exactly two products, both once-weekly injections shipped as a four-week vial supply: compounded semaglutide and compounded tirzepatide. The wider catalog lists 33 compounds, but the other 31 belong to different verticals entirely — hormone therapy, prescription skincare, longevity, sexual health, hair, and performance — and none of them is a GLP-1. There is no oral GLP-1 tablet here, despite older descriptions suggesting one, so anyone shopping for a needle-free route should start somewhere else.

Coverage is published now rather than left to guesswork: all 50 US states, adults 18 and older, stated sitewide and again on the pricing page. One detail is still not published. The plan table calls the monthly plan a one-month supply while both product pages describe a four-week vial, and no page says which of the two the billing follows — a four-week cycle would mean 13 charges in a year rather than 12, so it is worth asking before you take the open-ended plan.

The math rewards commitment sharply. A year of semaglutide bought a month at a time — $149 to start, then $165 — is $1,964, against $1,188 prepaid: $776 for making the decision once. The same year of tirzepatide is $2,547 monthly against $2,148 prepaid. But the prepaid figure leaves your account in a single charge, and the cheapest honest way to find out whether you tolerate the drug is still that $149 or $193 first month. Someone who has been on a GLP-1 before and knows they will stay on it is who the annual rung is built for; someone starting from scratch should ignore the $99 for now and buy one month.